HRMY Stock Risk & Deep Value Analysis
Harmony Biosciences Holdings Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About HRMY Stock
We analyzed Harmony Biosciences Holdings Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran HRMY through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Moderate. Here's what we found.
How Risky Is HRMY Stock?
Overall Risk
Moderate
Financial Risk
Low
Market Risk
Medium
Competitive Risk
Medium
Execution Risk
Medium
Regulatory Risk
Low
What Are the Red Flags for HRMY?
- ⚠
Slower-than-anticipated commercial ramp-up or adoption of WAKIX for IH
- ⚠
Emergence of new, highly effective competitive therapies in narcolepsy or IH market
- ⚠
Unfavorable clinical trial results for WAKIX in new indications
- ⚠
Unexpected regulatory hurdles or patent challenges
Unlock HRMY Red Flags & Risk Warnings
Create a free account to see the full analysis
What Does Harmony Biosciences Holdings Inc (HRMY) Do?
Market Cap
$1.55B
Sector
Healthcare
Industry
Biotechnology
Employees
268
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 1 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and High-Dose (HD). In addition, the company's products under development include BP1.15205, an orexin 2 receptor agonist for the treatment of narcolepsy and other potential indications; and HBS-102, a melanin-concentrating hormone receptor type 1 (MCHR1) antagonist. Further, it develops ZYN-002 that is in a Phase 3 registrational trial for the treatment of Fragile X Syndrome (FXS), rare genetic disorder that causes inherited intellectual disability and autism spectrum disorder; and 22q Deletion Syndrome, a disorder caused by a small missing piece on the long arm of the 22nd chromosome. Additionally, the company is developing EPX-100 (clemizole hydrochloride), a serotonin (5HT-2) receptor agonist to treat dravet syndrome and lenox-gastaut syndrome; and EPX-200 (liquid formulation of lorcaserin), a selective 5HT-2C agonist to treat developmental and epileptic encephalopathies (DEE). The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
Visit Harmony Biosciences Holdings Inc WebsiteIs HRMY Stock Undervalued?
Unlock the full AI analysis for HRMY
Get the complete DVR score, risk analysis, and more
Is HRMY Financially Healthy?
P/E Ratio
8.70
Does HRMY Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Stable to Expanding
Moat Sources
3 Identified
WAKIX's distinct non-scheduled mechanism of action provides a significant and durable competitive edge over traditional stimulants and sedatives. Its current patent protection extends well into the 2030s, allowing ample time for further market penetration and potential lifecycle management, making the moat robust for the next 10-15 years.
Moat Erosion Risks
- •Eventual patent expiry of WAKIX
- •Introduction of next-generation therapies (e.g., highly specific orexin receptor agonists) with superior efficacy or safety profiles
- •Increased competitive intensity in the sleep disorder treatment landscape
HRMY Competitive Moat Analysis
Sign up to see competitive advantages
What Could Drive HRMY Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings (Estimated early May 2026)
- •Updates on initial Idiopathic Hypersomnia (IH) commercial uptake and prescription trends
- •Potential WAKIX label expansion study updates (e.g., pediatric narcolepsy, other sleep disorders)
Medium-Term (6-18 months)
- •Continued robust growth and market penetration of WAKIX in Narcolepsy and IH
- •Announcements regarding new clinical development programs or pipeline acquisitions
- •Strategic partnerships to expand WAKIX's global reach or explore new indications
Long-Term (18+ months)
- •Successful diversification of pipeline beyond WAKIX through internal R&D or M&A
- •Establishment of WAKIX as a leading standard of care across multiple sleep/neurological disorders
- •Leveraging cash flow for share buybacks or dividend initiation, signaling maturity and confidence
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for HRMY?
- ✓
Acceleration in IH prescription growth rates and market share capture
- ✓
Announcements of new strategic M&A activities or significant pipeline advancements (e.g., new clinical trials for WAKIX in other indications, or acquisition of new assets)
- ✓
Continued strong cash flow generation and prudent capital allocation
- ✓
Any signs of increasing institutional ownership or positive analyst revisions.
Bull Case Analysis
See what could go right with Premium
Compare HRMY to Similar Stocks
See how Harmony Biosciences Holdings Inc stacks up against related companies in our head-to-head analysis.
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for HRMY (Harmony Biosciences Holdings Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.
